Table 1.
Baseline Characteristics of Study Participants
| Characteristics | Treatment-naïve (N = 2) | Virologically Suppressed (N = 43) | Total (N = 45) |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Sex | |||
| Male | 1 (50.0) | 18 (41.9) | 19 (42.2) |
| Female | 1 (50.0) | 25 (58.1) | 26 (57.8) |
| Ethnicity | |||
| Hispanic or Latino | 0 (0) | 1 (2.3) | 1 (2.2) |
| Not Hispanic or Latino | 2 (100.0) | 42 (97.7) | 44 (97.8) |
| Geography | |||
| Africa | 0 (0) | 9 (20.9) | 9 (20.0) |
| Asia/Pacific | 2 (100.0) | 33 (76.7) | 35 (77.8) |
| North America | 0 (0) | 1 (2.3) | 1 (2.2) |
| Class of Prior ART | |||
| NRTI | 0 (0) | 43 (100.0) | 43 (95.6) |
| NNRTI | 0 (0) | 32 (74.4) | 32 (71.1) |
| INSTI | 0 (0) | 1 (2.3) | 1 (2.2) |
| PI | 0 (0) | 10 (23.3) | 10 (22.2) |
| Not applicable | 2 (100.0) | 0 (0) | 2 (4.4) |
| Variables | Median (min, max) | Median (min, max) | Median (min, max) |
| Duration of prior ART (years) | - | 2.8 (0.3, 14.9) | 2.8 (0.3, 14.9) |
| Age (years) | 15.5 (14, 17) | 15 (12, 17) | 15 (12, 17) |
| Weight at baseline (kg) | 59.3 (53.3, 65.2) | 51.5 (45.1, 79.8) | 51.6 (45.1, 79.8) |
| CD4 cell count (cells/mm3) | 99 (84, 114) | 715 (315, 1397) | 713 (84, 1397) |
| CD4 percent (%) | 7.6 (5.7, 9.5) | 34.4 (18.9, 50.0) | 34.2 (5.7, 50.0) |
| HIV-1 RNAa (log10 copies/mL) | 5.8 (5.7, 5.9) | 1.6 (1.6, 1.6) | 1.6 (1.6, 5.9) |
Abbreviations: N, number of participants in each group; n (%), number (percent) of participants in each subcategory; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; INSTI, integrase strand transfer inhibitor; PI, protease inhibitor.
aSince the assay’s lower limit of quantification is 40 copies/mL, all participants with HIV-1 RNA value of <40 copies/mL are imputed as having 39 copies/mL.